COMPARACIÓN DEL RECHAZO AGUDO DURANTE EL PRIMER AÑO DEL INJERTO EN PACIENTES TRASPLANTADOS RENALES QUE RECIBIERON BASILIXIMAB O DACLIZUMAB. HOSPITAL CALDERÓN GUARDIA. PERÍODO 2000-2008

Background Acute renal transplant rejection isone of the most important complications of thismedical procedure. This study compares the first year rate of rejection in patients that receiveddaclizumab or basiliximab as initial immunosuppression induction drug. Methods It ́s an observational, retrosp...

Descripción completa

Autores Principales: Umaña González, Jorge Andrés, Mora Palma, Francisco, Espinach Roel, Mario
Formato: Artículo
Idioma: Español
Publicado: 2015
Materias:
Acceso en línea: http://revistas.ucr.ac.cr/index.php/clinica/article/view/6509
http://hdl.handle.net/10669/14725
Sumario: Background Acute renal transplant rejection isone of the most important complications of thismedical procedure. This study compares the first year rate of rejection in patients that receiveddaclizumab or basiliximab as initial immunosuppression induction drug. Methods It ́s an observational, retrospectivecohort study and includes patients between January 2000 and December 2008. The source ofpatients was the Nephrology Service of Calderón Guardia Hospital. The target population was allthe patients with renal transplant whom receivedbasiliximab or daclizumab as initial immunosuppression induction drug. Results Acute renal transplant rejection wasmore often seen in the group of patients thatreceived basiliximab, compared with the daclizumab group. Discussion The acute renal rejection rate in thefirst year post surgery in Calderón Guardia Hospital, showed statistically significant differencesbetween the daclizumab group and the basiliximab group. In the basiliximab group there wheremore patients with acute rejection.